Cilostazol丨CAS 73963-72-1

Cilostazol丨CAS 73963-72-1
Product Introduction:
Catalog No.: SS130867
CAS No.: 73963-72-1
Grade: USP43
Product Name: Cilostazol
Molecular Formula: C20H27N5O2
Molecular Weight: 369.46
Send Inquiry
Technical Parameters
Description

Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of cilostazol丨cas 73963-72-1 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.

 

Specifications

 

Grade USP43
Characters White to light yellow crystalline powder
Assay by HPLC (on dried basis) 98% to 102%
Identification A The IR spectrum is consistent with that obtained with Cilostazol RS
Identification B The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation
Loss on Drying 0.3% max
Residue on Ignition 0.1% max
Chloride 0.018% max
Heavy Metals 0.001% max
Particle size 90% less than 10 μm; 10% less than 20 μm
Impurity A 0.1% max
Impurity B 0.1% max
Impurity C 0.1% max
Any other individual impurity 0.1% max
Total impurities 0.4% max
Residual Solvents
N, N-Dimethylacetamide 1090 ppm max
Chloroform 60 ppm max
Ethanol 3000 ppm max
Methanol 3000 ppm max
Microbial Limits
Total aerobic microbial count 2000 cfu/g max
Total combined molds & yeasts 200 cfu/g max
Other specific microorganisms Absent (E.Coli, Salmonella sp)

 

 

 

Applications

 

Cilostazol is primarily used as a therapeutic agent for the management of peripheral arterial disease and intermittent claudication, improving blood flow and walking distance in affected patients. It functions as a phosphodiesterase III inhibitor, which leads to vasodilation and inhibition of platelet aggregation. Cilostazol is formulated in oral tablets for chronic therapy and is also investigated in combination with other cardiovascular drugs for the treatment of stroke, coronary artery disease, and other vascular disorders. Beyond clinical applications, it is utilized in pharmaceutical research for developing new derivatives targeting vascular health and antiplatelet therapy.

 

Benefits

 

The benefits of Cilostazol include its dual action of vasodilation and antiplatelet activity, which helps improve circulation and reduce the risk of thrombotic events. By inhibiting platelet aggregation without significant effects on coagulation factors, it lowers the risk of bleeding complications compared to some other antiplatelet agents. It enhances walking distance and overall exercise tolerance in patients with peripheral artery disease, improving quality of life. Cilostazol also exhibits a favorable safety profile and is well tolerated in long-term use, making it suitable for chronic cardiovascular management.

 

Conclusion

 

Cilostazol is a valuable cardiovascular drug that supports vascular health and improves mobility in patients with peripheral arterial disease. Its benefits, including vasodilation, antiplatelet activity, and safety in long-term use, make it an important option in cardiovascular therapy. By enhancing circulation and reducing thrombotic risks, Cilostazol continues to play a significant role in improving patient outcomes and managing vascular disorders.

 

 

Send Inquiry
Beyond Your Expectation
From Science to Life with LEAPChem
contact us